ESMO Sarcoma and Rare Cancers 2023 | GRM4 regulation of interleukin-23 as a novel target for osteosarcoma

David Thomas, PhD, FRACP, The Kinghorn Cancer Centre, Sydney, Australia, discusses the genetic association between GRM4 and osteosarcoma and how it has led to our understanding of GRM4-regulated interleurkin-23 as a driver of tumor pathophysiology. As mouse studies have demonstrated that interleukin-23 knockout exerts a protective role in rodent osteosarcoma, an ongoing clinical trial with Prof. Thomas proposes that antagonism of this cytokine in humans may yield similar therapeutic potential. This interview took place at the 2023 ESMO annual Sarcoma and Rare Cancers congress in Lugano, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.